Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The EINSTEIN CYP Cohort Study Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism Using a Strong CYP 3A4 Inducer.

Trial Profile

The EINSTEIN CYP Cohort Study Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism Using a Strong CYP 3A4 Inducer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms EINSTEIN-CYP
  • Sponsors Bayer

Most Recent Events

  • 01 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 10 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 10 Jan 2011 Planned end date changed from Mar 2011 to Jun 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top